TROG 14.01 - ENZARAD - TROG Cancer Research

By w.paterson
21 June, 2021
0 Comments

Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer

Primary Sponsor

ANZUP

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre

Accrual Target

800

Final Accrual

802

Closing Date of Accrual

30 June 2018

Trial Contact

enzarad.study@sydney.edu.au

Geoff Zipper - aka Swamp - on the Kokoda Trail

26 June, 2025

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

TROG 2024 Annual Research Report highlights a year of achievements

LATEST NEWS: 24 JUNE 2025 The latest annual report

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer

TROG 14.02 – RAIDER

TROG 12.02 – PET LABRADOR

Related Post

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

TROG 2024 Annual Research Report highlights a year of achievements